Surveillance
- •
Patients at high risk for developing HCC should be entered into surveillance programs. Groups at high risk are depicted in Table 3 (evidence 1B/3A; recommendation 1A/B)
- •
Surveillance should be performed by experienced personnel in all at-risk populations using abdominal ultrasound every 6
- •
Clinical Practice GuidelinesEASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma☆
Introduction
EASL–EORTC Clinical Practice Guidelines (CPG) on the management of hepatocellular carcinoma (HCC) define the use of surveillance, diagnosis and therapeutic strategies recommended for patients with this type of cancer. This is the first European joint effort by the European Association for the Study of the Liver (EASL) and the European Organisation for Research and Treatment of Cancer (EORTC) to provide common guidelines for the management of hepatocellular carcinoma. These guidelines update the recommendations reported by the EASL panel of experts in HCC published in 2001.1 Several clinical and scientific advances have occurred during the past decade and, thus, a modern version of the document is urgently needed.
The purpose of this document is to assist physicians, patients, health-care providers and health-policy makers from Europe and worldwide in the decision-making process according to evidence-based data. Users of these guidelines should be aware that the recommendations are intended to guide clinical practice in circumstances where all possible resources and therapies are available. Thus, they should adapt the recommendations to their local regulations and/or team capacities, infrastructure and cost–benefit strategies. Finally, this document sets out some recommendations that should be instrumental in advancing the research and knowledge of this disease and ultimately contribute to improve patient care.
The EASL–EORTC CPG on the management of hepatocellular carcinoma provide recommendations based on the level of evidence and the strength of the data (the classification of evidence is adapted from the National Cancer Institute2) (Table 1A) and the strength of recommendations following previously reported systems (GRADE systems) (Table 1B).
Section snippets
Clinical Practice Summary
The clinical practice guidelines below will give advice for up to date management of patients with HCC as well as providing an in-depth review of all the relevant data leading to the conclusions.
Epidemiology, risk factors and prevention
The incidence of HCC is increasing in Europe and worldwide Vaccination against hepatitis B is recommended to all newborns and high risk groups (evidence: 2D; recommendation 1A) Governmental health agencies should recommend policies for preventing HCV/HBV transmissions, encourage life styles preventing obesity and alcohol abuse (evidence 3A; recommendation 1A) and controlling metabolic conditions, such as diabetes (evidence 3; recommendation 2B) In patients with chronic hepatitis, antiviral
Surveillance
Implementation of surveillance programmes to identify at-risk candidate populations and identification of biomarkers for early HCC detection are a major public health goal to decrease HCC-related deaths (evidence 1D; recommendation 1B). Government health policy and research agencies should address these needs Patients at high risk for developing HCC should be entered into surveillance programmes. Groups at high risk are depicted in Table 3 (evidence 1B/3A; recommendation 1A/B) Surveillance should
Diagnosis
Diagnosis of HCC is based on non-invasive criteria or pathology (evidence 2D; recommendation 1A). Pathological diagnosis of HCC is based on the recommendations of the International Consensus Panel. Immunostaining for GPC3, HSP70 and glutamine synthetase and/or gene expression profiles (GPC3, LYVE1 and survivin) are recommended to differentiate high grade dysplastic nodules from early HCC (evidence 2D; recommendation 2B). Additional staining can be considered to detect progenitor cell features
Staging systems
Staging systems in HCC should define outcome prediction and treatment assignment. They should facilitate exchange of information, prognosis prediction and trial design. Due to the nature of HCC, the main prognostic variables are tumour stage, liver function and performance status. The BCLC staging system is recommended for prognostic prediction and treatment allocation (evidence 2A; recommendation 1B). This staging system can be applied to most HCC patients, as long as specific considerations
Treatment
Treatment allocation is based on the BCLC allocation system, and the levels of evidence of treatments according to strength and magnitude of benefit are summarised in Fig. 4.
In oncology, the benefits of treatments should be assessed through randomised controlled trials and meta-analysis. Other sources of evidence, such as non-randomised clinical trials or observational studies are considered less robust. Few medical interventions have been thoroughly tested in HCC, in contrast with other
Resection
Resection is the first-line treatment option for patients with solitary tumours and very well-preserved liver function, defined as normal bilirubin with either hepatic venous pressure gradient ⩽10 mmHg or platelet count ⩾100,000 (evidence 2A; recommendation 1B) Anatomical resections are recommended (evidence 3A; recommendation 2C). Additional indications for patients with multifocal tumours meeting Milan Criteria (⩽3 nodules ⩽3 cm) or with mild portal hypertension not suitable for liver
Liver transplantation
Liver transplantation is considered to be the first-line treatment option for patients with single tumours less than 5 cm or ⩽3 nodules ⩽3 cm (Milan criteria) not suitable for resection (evidence 2A; recommendation 1A). Peri-operative mortality and one-year mortality are expected to be approximately 3% and ⩽10%, respectively. Extension of tumour limit criteria for liver transplantation for HCC has not been established. Modest expansion of Milan criteria applying the “up-to-seven” in patients
Local ablation
Local ablation with radiofrequency or percutaneous ethanol injection is considered the standard of care for patients with BCLC 0-A tumours not suitable for surgery (evidence 2A; recommendation 1B). Other ablative therapies, such as microwave or cryoablation, are still under investigation. Radiofrequency ablation is recommended in most instances as the main ablative therapy in tumours less than 5 cm due to a significantly better control of the disease (evidence 1iD; recommendation 1A). Ethanol
Chemoembolisation and transcatheter therapies
Chemoembolisation is recommended for patients with BCLC stage B, multinodular asymptomatic tumours without vascular invasion or extra hepatic spread (evidence 1iiA; recommendation 1A) The use of drug-eluting beads has shown similar response rates than gelfoam-lipiodol particles associated with less systemic adverse events (evidence 1D; recommendation 2B) Chemoembolisation is discouraged in patients with decompensated liver disease, advanced liver dysfunction, macroscopic invasion or
Systemic therapies
Sorafenib is the standard systemic therapy for HCC. It is indicated for patients with well-preserved liver function (Child-Pugh A class) and with advanced tumours (BCLC C) or those tumours progressing upon loco-regional therapies (evidence 1iA; recommendation 1A). There are no clinical or molecular biomarkers available to identify the best responders to sorafenib (evidence 1A; recommendation 2A). Systemic chemotherapy, tamoxifen, immunotherapy, anti-androgen, and herbal drugs are not recommended
Trial design
The panel endorses the trial design and selection of end points for clinical trials in HCC proposed in previous JNCI guidelines (Fig. 5) and lists the high-end trials currently ongoing which, in case of demonstrating clinically relevant superiority vs. the standard of care, might change the current guidelines (Table 4). Assessment of response: Assessment of response in HCC should be based on the modification of the RECIST criteria (mRECIST; Table 5) (recommendation 2B). Use of changes in serum
Final considerations
The panel considers that collection of tissue and serum samples in research studies is highly desirable and recommended. Such biobanking should permit the achievement of two clinical goals: Refinement of prognostication and BCLC staging system. Molecular data such as gene signatures (poor survival, EpCAM) or biomarkers (AFP, VEGF, Ang2 and miR26) have been shown to have independent prognostic significance and are likely to be incorporated into staging systems after external independent
Addendum
During the editing process of the guidelines additional information on two phase 3 RCT mentioned in Table 4 was reported.
- 1.
The study comparing brivanib vs. placebo in patients with advanced HCC failing or intolerant to sorafenib was reported not meeting the primary end-point survival. http://www.businesswire.com/portal/site/home/email/alert (Jan 2012).
- 2.
The study comparing linifanib vs. sorafenib in first-line was halted by the DSMC at the interim analysis. (Abbott’s LiGHT (Linifanib Study M10-963)
Disclosures
These guidelines reflect the state of knowledge, current at the time of publication, on effective and appropriate care, as well as clinical consensus judgments when knowledge is lacking. The inevitable changes in the state of scientific information and technology mandate that periodic review, updating, and revisions will be needed. These guidelines do not apply to all patients, and each must be adapted and tailored to each individual patient. Proper use, adaptation modifications or decisions to
Conflict of interest
Josep M. Llovet has received research support, and/or lecture and/or consultant fees and/or took part in clinical trials for Bayer Pharmaceutical, BMS, Biocompatibles, Novartis, Abbot, Imclone, Jennerex. Michel Ducreux has received research support, and/or lecture fees and/or took part in clinical trials for Bayer and Abbot. Mauro Bernardi has nothing to disclose. Thierry de Baére has received lecture fees for Terumo, Biocompatibles, Bayer. Arian Di Bisceglie has received research support,
Acknowledgements
The contributors thank the EASL office and the Journal of Hepatology editorial office for editorial assistance.
References (360)
- et al.
EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona–2000 EASL conference. European Association for the Study of the Liver
J Hepatol
(2001) - et al.
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease
Gastroenterology
(2009) - et al.
Portal Hypertension Collaborative Group. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis
J Hepatol
(2009) - et al.
Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer–In HBV (the REVEAL–HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load
Gastroenterology
(2006) - et al.
Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis
J Hepatol
(2009) - et al.
Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases
Gastroenterology
(1993) - et al.
Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma
J Hepatol
(2005) - et al.
Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption
J Hepatol
(2008) EASL Clinical Practice Guidelines: Management of Chronic Hepatitis B
J Hepatol
(2009)- et al.
Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy
Hepatology
(2001)
Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis
Lancet
EPIC3 Study Group. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C
Gastroenterology
Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis
Am J Med
Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance
Gastroenterology
Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis
Hepatology
Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors
J Hepatol
Primary liver cancer: worldwide incidence and trends
Gastroenterology
Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma
Clin Gastroenterol Hepatol
Prevention of hepatocellular carcinoma
Clin Liver Dis
Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients
Gastroenterology
Screening for hepatocellular carcinoma in cirrhosis
J Hepatol
Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma
J Hepatol
Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients
Hepatology
Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study
Hepatology
HALT-C Trial Group. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C trial
J Hepatol
Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HbsAg and anti–HCV status
J Hepatol
Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis
J Hepatol
Natural history of minute hepatocellular carcinoma smaller than three centimetres complicating cirrhosis. A study in 22 patients
Gastroenterology
Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications
Gastroenterology
A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus
Blood
Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patients survival (Italian experience)
Am J Gastroenterol
Italian Liver Cancer (ITA.LI.CA) Group. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival
J Hepatol
Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis
Clin Gastroenterol Hepatol
Hepatocellular carcinoma
Lancet
Global cancer statistics, 2002
CA Cancer J Clin
Declining incidence of hepatocellular carcinoma in Osaka, Japan from 1990 to 2003
Ann Intern Med
Trends in mortality from hepatocellular carcinoma in Europe, 1980–2004
Hepatology
Cancer Statistics, 2008
CA Cancer J Clin
Taiwan Hepatoma Study Group. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study
J Natl Cancer Inst
The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients
Hepatology
Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis
Clin Gastroenterol Hepatol
Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography
Hepatology
Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan)
Hepatology
Prevention of hepatitis B virus-related hepatocellular carcinoma
Gastroenterology
Taiwan Community-Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma
N Engl J Med
REVEAL–HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
JAMA
Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men
J Natl Cancer Inst
Cited by (408)
Extracellular vesicles associated microRNAs: Their biology and clinical significance as biomarkers in gastrointestinal cancers
2024, Seminars in Cancer BiologyHepatocellular carcinoma recurrence: Predictors and management
2023, Liver ResearchResearch progress and application of the CRISPR/Cas9 gene-editing technology based on hepatocellular carcinoma
2023, Asian Journal of Pharmaceutical SciencesStage-by-stage analysis of the effect of blood transfusion on survival after curative hepatectomy for hepatocellular carcinoma—a retrospective study
2024, Langenbeck's Archives of Surgery
- ☆
These Guidelines were developed by the EASL and the EORTC and are published simultaneously in the Journal of Hepatology (volume 56, issue 4) and the European Journal of Cancer (volume 48, issue 5).
Contributors: Chairmen: Josep M. Llovet (EASL); Michel Ducreux (EORTC). Clinical Practice Guidelines Members: Riccardo Lencioni; Adrian M. Di Bisceglie; Peter R. Galle; Jean Francois Dufour; Tim F. Greten; Eric Raymond; Tania Roskams; Thierry De Baere; Michel Ducreux and Vincenzo Mazzaferro. EASL Governing Board Representatives: Mauro Bernardi. Reviewers: Jordi Bruix; Massimo Colombo; Andrew Zhu.
∗Correspondence to: EASL Office, 7 rue des Battoirs, CH 1205 Geneva, Switzerland. Tel.: +41 22 807 0360; fax: +41 22 328 0724.
E-mail address: [email protected] (European Association for the Study of the Liver).